Browse News
Filter News
Found 808,856 articles
-
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
-
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
-
Bristol Myers Squibb will be using Cellares’ Cell Shuttles, an automated production system capable of producing multiple cell therapies simultaneously, to potentially improve turnaround time to support the pharma’s CAR T cell therapies.
-
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
-
A one-time treatment for Parkinson’s disease could be a ‘market changer,’ experts told BioSpace, adding that cell therapies could limit the adverse effects seen with current drugs.
-
From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
-
While Madrigal Pharmaceuticals secured the first FDA drug approval for metabolic dysfunction–associated steatohepatitis, Akero Therapeutics is developing what may serve as a viable alternative treatment for precirrhotic disease.
-
Bolstered by its portfolio of “revolutionary” therapies, AbbVie remains the top pharma company in the immunology space, according to a new survey of doctors by ZoomRx.
-
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
-
As AbbVie and NeuroDerm race toward potential U.S. approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions.
-
QT Imaging Holdings (Nasdaq: QTI) to Ring The Nasdaq Stock Market Opening Bell
4/22/2024
QT Imaging Holdings, Inc., a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
-
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
4/22/2024
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET.
-
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
4/22/2024
OraSure Technologies, Inc. has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
4/22/2024
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024.
-
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
4/22/2024
Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 Inhibitor Suitable for Clinical Assessment”.
-
Zydus launches Mirabegron Extended-Release Tablets in the US
4/22/2024
Zydus Lifesciences Limited announces the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market.
-
Amarin Announces Results of Annual General Meeting of Shareholders
4/22/2024
Amarin Corporation plc announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting.
-
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
4/22/2024
Oryzon Genomics, S.A. announced that the European Patent Office has issued an “intention to grant” communication for Oryzon’s European patent application EP18748921.6 entitled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.